Two-phase study reveals elevated Krebs von den Lungen-6 predicts exacerbation frequency in COPD, suggesting personalized strategies.
Objective To evaluate the potential of systemic Krebs von den Lungen-6 level in predicting acute exacerbations of chronic obstructive pulmonary disease. Methods This two-phase study included a derivation phase (January 2022 to December 2022) involving 156 patients with stable chronic obstructive pulmonary disease, in which optimal Krebs von den Lungen-6 thresholds were identified through multivariate modeling. Serum levels of Krebs von den Lungen-6 and surfactant protein D were analyzed for correlations with exacerbation frequency, Chronic Obstructive Pulmonary Disease Assessment Test score, modified British Medical Research Council score, forced expiratory volume in 1 second percent predicted, and forced expiratory volume in 1 second/forced vital capacity ratio. Prospective validation was performed in a separate cohort (January 2023 to December 2023, n = 121) stratified by Krebs von den Lungen-6 thresholds. Results Krebs von den Lungen-6 and surfactant protein D levels were significantly correlated with exacerbation frequency, Chronic Obstructive Pulmonary Disease Assessment Test, and modified British Medical Research Council scores and were inversely associated with forced expiratory volume in 1 second percent predicted and forced expiratory volume in 1 second/forced vital capacity ratio. Multivariate analysis identified Krebs von den Lungen-6, but not surfactant protein D, as an independent predictor of high-exacerbation phenotypes (≥2 events/year). In the validation phase, the high-Krebs von den Lungen-6 group (≥400.5 U/mL) exhibited significantly higher annual exacerbation rates than the low-Krebs von den Lungen-6 group after adjustment for baseline characteristics. Conclusions Serum Krebs von den Lungen-6 at ≥400.5 U/mL is an independent risk factor for frequent exacerbations of chronic obstructive pulmonary disease. Its association with inflammatory markers and lung function decline suggests potential utility in personalized treatment strategies.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: